Nkcfo LLC Makes New $47,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Nkcfo LLC purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 590 shares of the medical equipment provider’s stock, valued at approximately $47,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of LNTH. UMB Bank n.a. grew its holdings in Lantheus by 161.4% in the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. GAMMA Investing LLC increased its position in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 208 shares in the last quarter. Principal Securities Inc. purchased a new stake in Lantheus in the fourth quarter valued at about $28,000. Fidelis Capital Partners LLC purchased a new stake in shares of Lantheus during the first quarter worth about $34,000. Finally, FinTrust Capital Advisors LLC boosted its stake in Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 232 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on LNTH shares. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Leerink Partners increased their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Truist Financial decreased their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, JMP Securities decreased their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Insider Transactions at Lantheus

In related news, Director Gary J. Pruden sold 12,530 shares of Lantheus stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the transaction, the director now owns 11,978 shares in the company, valued at $1,138,389.12. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gary J. Pruden sold 12,530 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the sale, the director now owns 11,978 shares of the company’s stock, valued at approximately $1,138,389.12. The disclosure for this sale can be found here. Insiders have sold a total of 40,852 shares of company stock worth $3,922,001 in the last ninety days. Insiders own 1.50% of the company’s stock.

Lantheus Stock Up 1.4 %

Shares of NASDAQ LNTH opened at $110.05 on Friday. The firm has a market cap of $7.63 billion, a price-to-earnings ratio of 16.80 and a beta of 0.50. The company’s 50-day simple moving average is $105.51 and its 200-day simple moving average is $84.10. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. During the same period in the prior year, the business posted $1.40 earnings per share. The business’s quarterly revenue was up 22.5% on a year-over-year basis. Equities analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.